A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Adults ≥ 18 Years Old Who Received 2 or more doses of Inactivated Covid-19 Vaccine - Trial PHRR220912-004985
Access comprehensive clinical trial information for PHRR220912-004985 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Yisheng Biopharma (Singapore) PTE. LTD. and is currently Ongoing. The study focuses on COVID-19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR220912-004985
Phase 2/3
Ongoing
Trial Details
Philippine Health Research Registry • PHRR220912-004985
A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Adults ≥ 18 Years Old Who Received 2 or more doses of Inactivated Covid-19 Vaccine
Study Focus
Interventional
Sponsor & Location
Yisheng Biopharma (Singapore) PTE. LTD.
Philippines United Arab Emirates
Timeline & Enrollment
Phase 2/3
Sep 26, 2022
N/A
ICD-10 Classifications
COVID-19, virus identified
COVID-19, virus not identified
Coronavirus infection, unspecified site
Viral infection, unspecified
Rift Valley fever
Data Source
Philippine Health Research Registry
PHRR220912-004985
Non-Device Trial